Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

Published by: GBI Research

Published: May. 18, 2012 - 140 Pages


Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Arthritis Therapeutics Market to 2018 - Introduction
3 Arthritis Therapeutics Market to 2018 - Market Overview
3.1 Introduction
3.2 Revenue Forecasts for the Global Arthritis Therapeutics Market
3.2.1 Revenue
3.2.2 Annual Cost of Treatment
3.3 Treatment Usage Patterns
3.3.1 Diseased Population
3.3.2 Treatment Seeking Population
3.3.3 Diagnosis Population
3.3.4 Prescription Population
4 Arthritis Therapeutics Market to 2018 - Therapeutic Landscape
4.1 Osteoarthritis Therapeutics Market
4.1.1 Introduction
4.1.2 Epidemiology
4.1.3 Symptoms
4.1.4 Diagnosis
4.1.5 Diagnostic Imaging Techniques
4.1.6 Treatment
4.1.7 Revenue
4.1.8 Annual Cost of Treatment
4.1.9 Treatment Usage Patterns
4.1.10 Marketed Products
4.2 Drivers and Barriers for the Osteoarthritis Therapeutics Market
4.2.1 Drivers for the Osteoarthritis Therapeutics Market
4.2.2 Barriers for the Osteoarthritis Therapeutics Market
4.3 Opportunity and Unmet Need
4.4 Arthritis Therapeutics Market
4.4.1 Introduction
4.4.2 Epidemiology
4.4.3 Symptoms
4.4.4 Diagnosis
4.4.5 Diagnostic Techniques
4.4.6 Treatment
4.4.7 Non-Pharmacological Therapy
4.4.8 Surgical Treatment
4.4.9 Pharmacological Therapy
4.4.10 Revenue
4.4.11 Annual Cost of Treatment
4.4.12 Treatment Usage Patterns
4.4.13 Marketed products
4.5 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market
4.5.1 Drivers for the Rheumatoid Arthritis Therapeutics Market
4.5.2 Barriers for the Rheumatoid Arthritis Therapeutics Market
4.6 Opportunity and Unmet Needs
4.7 Psoriatic Arthritis Therapeutics Market
4.7.1 Introduction
4.7.2 Epidemiology
4.7.3 Symptoms
4.7.4 Diagnosis
4.7.5 Diagnostic Techniques
4.7.6 Treatment
4.7.7 Non-Pharmacological Therapy
4.7.8 Pharmacological Therapy
4.7.9 Surgery
4.7.10 Revenue
4.7.11 Annual Cost of Treatment
4.7.12 Treatment Usage Patterns
4.7.13 Marketed Products
4.8 Drivers and Barriers for the Psoriatic Arthritis Therapeutics Market
4.8.1 Drivers for the Psoriatic Arthritis Therapeutics Market
4.8.2 Barriers for the Psoriatic Arthritis Therapeutics Market
4.9 Opportunity and Unmet Needs
4.10 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Market
4.10.1 Introduction
4.10.2 Epidemiology
4.10.3 Symptoms
4.10.4 Diagnosis
4.10.5 Treatment
4.10.6 Non-Pharmacological Therapy
4.10.7 Pharmacological Therapy
4.10.8 Surgery
4.10.9 Revenue
4.10.10 Annual Cost of Treatment
4.10.11 Treatment Usage Patterns
4.10.12 Marketed products
4.11 Drivers and Barriers for the Ankylosing Spondylitis Therapeutics Market
4.11.1 Drivers for the Ankylosing Spondylitis Therapeutics Market
4.11.2 Barriers for the Ankylosing Spondylitis Therapeutics Market
4.12 Opportunity and Unmet Need
5 Arthritis Therapeutics Market to 2018 - Geographical Landscape
5.1 Revenue Analysis by Geography
5.2 The US
5.2.1 Revenue
5.2.2 Annual Cost of Treatment
5.2.3 Treatment Usage Patterns
5.3 Top Five European countries (UK, Germany, France, Italy and Spain)
5.3.1 Revenue
5.3.2 Annual Cost of Treatment
5.3.3 Treatment Usage Patterns
5.4 Japan
5.4.1 Revenue
5.4.2 Annual Cost of Treatment
5.4.3 Treatment Usage Patterns
6 Arthritis Therapeutics Market to 2018 - Product Pipeline Analysis
6.1 Introduction
6.1.1 Research and Development Pipeline – Osteoarthritis
6.2 Introduction
6.2.1 Research and Development Pipeline – Rheumatoid Arthritis
6.3 Introduction
6.3.1 Research and Development Pipeline – Psoriasis Arthritis
6.4 Introduction
6.4.1 Research and Development Pipeline – Ankylosing Spondylitis
6.5 Profiles of Promising Drugs in the Pipeline
6.5.1 Tofacitinib (CP-690550)
6.5.2 Ofatumumab
6.5.3 Secukinumab (AIN457)
6.5.4 Fostamatinib (R788)
6.5.5 LY2127399 (Tabalumab)
6.5.6 REGN88 (SAR153191)
6.5.7 LT-NS001
7 Arthritis Therapeutics Market to 2018 - Competitive Landscape
7.1 Market Share Analysis
7.1.1 Major Players
7.2 Competitive Profile
7.2.1 Roche
7.2.2 Johnson & Johnson
7.2.3 Pfizer
7.2.4 Abbott Laboratories
7.2.5 Bristol-Myers Squibb
7.2.6 Amgen
8 Arthritis Therapeutics Market to 2018 - Strategic Consolidations
8.1 Mergers and Acquisitions
8.1.1 Overview
8.1.2 Major Merger and Acquisition Deals
8.1.3 Possible Future Merger and Acquisition Deals
8.2 Licensing Agreements
8.2.1 Overview
8.2.2 Major Licensing Deal
8.3 Co-Development Agreements
8.4 Deals by Geography
8.5 Deals by Value
9 Arthritis Therapeutics Market to 2018 - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Sources
9.4 Research Methodology
9.4.1 Coverage
9.4.2 Secondary Research
9.4.3 Primary Research
9.4.4 Forecasts
9.4.5 Expert Panel Validation
9.5 Contact Us
9.6 Disclaimer
1.1 List of Tables
Table 1: Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010
Table 2: Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018
Table 3: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010
Table 4: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018
Table 5: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010
Table 6: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018
Table 7 : Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010
Table 8: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018
Table 9: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010
Table 10: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018
Table 11: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010
Table 12: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018
Table 13: Osteoarthritis Therapeutics Market, Marketed Products, 2010
Table 14: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010
Table 15: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018
Table 16: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010
Table 17: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018
Table 18: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010
Table 19: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018
Table 20: Rheumatoid Arthritis Therapeutics-Marketed Products, 2010
Table 21: Psoriatic Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010
Table 22: Psoriatic Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018
Table 23: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010
Table 24: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018
Table 25: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010
Table 26: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018
Table 27: Psoriatic Arthritis Therapeutics-Marketed Products, 2010
Table 28: Ankylosing Spondylitis Therapeutics Market, Global, Revenue ($m), 2004-2010
Table 29: Ankylosing Spondylitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018
Table 30: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010
Table 31: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018
Table 32: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010
Table 33: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018
Table 34: Ankylosing Spondylitis Therapeutics-Marketed Products, 2010
Table 35: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2004-2010
Table 36: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2018
Table 37: Arthritis Therapeutics Market, The US, Revenue ($bn), 2004-2010
Table 38: Arthritis Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2018
Table 39: Arthritis Therapeutics Market, The US Market, Annual Cost of Treatment ($), 2004-2010
Table 40: Arthritis Therapeutics Market, The US Market, Annual Cost of Treatment ($), 2010-2018
Table 41: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2004-2010
Table 42: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2018
Table 43: Arthritis Therapeutics Market, Top Five EU Countries, Revenue ($bn), 2004-2010
Table 44: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2010-2018
Table 45: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2004-2010
Table 46: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2010-2018
Table 47: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2004-2010
Table 48: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2010-2018
Table 49: Arthritis Therapeutics Market, Japan, Revenue ($bn), 2004-2010
Table 50: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2010-2018
Table 51: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2010
Table 52: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2018
Table 53: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2004-2010
Table 54: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2018
Table 55: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011
Table 56: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011
Table 57: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Develoment Stage Molecules, 2011
Table 58: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011
Table 59: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011
Table 60: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011
Table 61: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011
Table 62: Arthritis Therapeutics Market, Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011
Table 63: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011
Table 64: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011
Table 65: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011
Table 66: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011
Table 67: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011
Table 68: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011
Table 69: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011
Table 70: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011
Table 71: Arthritis Therapeutics Market-Psoriatic Arthritis Pipeline, Development Stage Molecules, 2011
Table 72: Arthritis Therapeutics Market-Psoriatic Arthritis Pipeline, Development Stage Molecules, 2011
Table 73: Arthritis Therapeutics Market- Ankylosing Spondylitis Pipeline, Development Stage Molecules, 2011
1.2 List of Figures
Figure 1: Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018
Figure 2: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018
Figure 3: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018
Figure 4: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018
Figure 5: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018
Figure 6: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018
Figure 7: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018
Figure 8: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018
Figure 9: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018
Figure 10: Psoriatic Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018
Figure 11: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018
Figure 12: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018
Figure 13: Ankylosing Spondylitis Therapeutics Market, Global, Revenue Forecasts ($m), 2004-2018
Figure 14: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018
Figure 15: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018
Figure 16: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2004-2018
Figure 17: Arthritis Therapeutics Market, The US, Revenue Forecasts ($bn), 2004-2018
Figure 18: Arthritis Therapeutics Market, The US, Annual Cost of Treatment ($), 2004-2018
Figure 19: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2004-2018
Figure 20: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2004-2018
Figure 21: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2004-2018
Figure 22: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2004-2018
Figure 23: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2004-2018
Figure 24: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2018
Figure 25:Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2004-2018
Figure 26:Arthritis Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011
Figure 27: Arthritis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011
Figure 28: Arthritis Therapeutics Market, Osteoarthritis Therapeutics, Global R&D Pipeline by Phase (%), 2011
Figure 29: Arthritis Therapeutics Market-Rheumatoid Arthritis, Global R&D Pipeline by Phase (%), 2011
Figure 30: Arthritis Therapeutics Market-Psoriatic Arthritis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011
Figure 31:Arthritis Therapeutics Market, Ankylosing Spondylitis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011
Figure 32:Arthritis Therapeutics Market, Global, Market Share of Top Six Companies (%), 2010
Figure 33:Arthritis Therapeutics Market, SWOT Analysis, Roche, 2011
Figure 34: Arthritis Therapeutics Market, SWOT Analysis, Johnson and Johnson Inc., 2011
Figure 35: Arthritis Therapeutics Market, SWOT Analysis, Pfizer, 2011
Figure 36: Arthritis Therapeutics Market, SWOT Analysis, Abbott Laboratories, 2011
Figure 37: Arthritis Therapeutics Market, SWOT Analysis, Bristol-Myers Squibb, 2011
Figure 38: Arthritis Therapeutics Market, SWOT Analysis, Amgen, 2011
Figure 39: Arthritis Therapeutics Market, Global, Major Licensing Agreements By Geography, 2009-2011
Figure 40: Arthritis Therapeutics Market, Global, Major Licensing Agreements by Value (%), 2009-2011
Figure 41: GBI Research Market Forecasting Model

Abstract

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

Summary

GBI Research’s new report, “Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications”, provides an expert insight into the global arthritis market and market forecast until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the top four arthritis therapeutic indications which are osteoarthritis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape of the top companies in the market and an analysis of the key trends in mergers and acquisitions, and licensing agreements involving arthritis therapies.

Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research analysis shows that the global arthritis therapeutics market was estimated at $20.6 billion in 2010, during the forecast period the market grow at a Compound Annual Growth Rate (CAGR) of 7.2% between 2010 and 2018 to a $38 billion. The market share of rheumatoid arthritis, osteoarthritis, psoriatic arthritis and ankylosing spondylitis in the overall arthritis market was 68%, 22%, 7.4% and 2.6%, respectively, in 2010. The rheumatoid arthritis market was $14 billion in 2010. The market revenue is expected to increase to $26.9 billion by 2018 at a CAGR of 8.5%. The osteoarthritis market is expected to show slower growth among the top four indications. Top six companies in the arthritis therapeutics market accounted for a share of close to 62% in 2010, leaving 38% of the market dominated by generic therapies and smaller players. Despite a significant number of products available on the market, the high value of biologics keeps the market value high.

GBI Research analysis shows that the Research and Development (R&D) pipeline for the arthritis therapeutics market is strong. The rich arthritis pipeline is likely to support the growth of this market thereby attracting many pharmaceutical and biotechnological companies. Major pharmaceutical companies such as Pfizer, Amgen, Merck, Roche and Novartis are already active in R&D for arthritis therapies.

Scope
  • Data and analysis of the arthritis market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the osteoarthritis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis markets from 2004 to 2010, with forecasts to 2018.
  • Market Data on geographical landscape and therapeutic landscape including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
  • Key drivers and restraints that have had a significant impact on the market
  • The competitive landscape of the arthritis market which includes companies such as Johnson & Johnson, Abbott, Amgen, Pfizer, Roche and Bristol-Myers Squibb.
  • Key M&A activities and licensing agreements that took place from 2005 to 2011 in the arthritis market.
Reasons to buy
  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
  • Device a more tailored country strategy by understanding the key drivers and barriers of the arthritis market.
  • Develop key strategic initiatives by understanding the key focus areas of the leading companies.
  • Accelerate and strengthen your market position by identifying the key companies for mergers, acquisitions and strategic partnerships.


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.